Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey.
Drug resistance
Nontuberculous mycobacteria
Prevalence
Pulmonary disease
Journal
Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
01
02
2021
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Information on the prevalence and resistance spectrum of nontuberculous mycobacteria (NTM) in China is mainly based on regional or local data. To estimate the proportion of NTM cases in China, a national survey of NTM pulmonary disease was carried out based on acid-fast positive sputum samples collected in 2013. Sputum samples collected from enrolled presumptive cases in 72 nationwide tuberculosis surveillance sites from the 31 provinces in the mainland of China were cultured using L-J medium at the National tuberculosis reference laboratory (NTRL). MALDI-TOF MS identified the species of re-cultured strains, and minimal inhibitory concentrations (MICs) were determined to evaluate the drug susceptibility of NTM isolates. Data analysis used statistical software SPSS version 22.0 for Windows statistical package. Of 4917 mycobacterial isolates cultured, 6.4% [317/4917, 95% confidence interval (CI) 5.8%-7.2%] were confirmed as NTM, among which 7.7% (287/3709, 95% CI 6.9%-8.6%) were from the southern region. In inland and coastal China, 87.7% (95% CI 78.7%-93.2%) and 50.0% (95% CI 43.7%-56.3%) of isolates, respectively, were slow-growing mycobacteria (SGM), with the remaining rapid growing mycobacteria (RGM). A total of 29 species were detected, Mycobacterium abscessus had higher clarithromycin-inducible resistance rates than M. massiliense (65.67% vs 2.22%). M. kansasii presented lower resistance rates in linezolid and moxifloxacin than M. avium-intracellulare complex (3.23% vs 66.67%, 0 vs 47.22%) and other SGM (3.23% vs 38%, 0 vs 26%). More NTM pulmonary disease was observed in the south and coastal China (P < 0.01). SGM was widely distributed, and more RGM are present in southern and coastal China (P < 0.01). The antimicrobial resistance spectrum of different NTM species was significantly different and accurate species identification would be facilitated to NTM pulmonary disease treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Information on the prevalence and resistance spectrum of nontuberculous mycobacteria (NTM) in China is mainly based on regional or local data. To estimate the proportion of NTM cases in China, a national survey of NTM pulmonary disease was carried out based on acid-fast positive sputum samples collected in 2013.
METHODS
METHODS
Sputum samples collected from enrolled presumptive cases in 72 nationwide tuberculosis surveillance sites from the 31 provinces in the mainland of China were cultured using L-J medium at the National tuberculosis reference laboratory (NTRL). MALDI-TOF MS identified the species of re-cultured strains, and minimal inhibitory concentrations (MICs) were determined to evaluate the drug susceptibility of NTM isolates. Data analysis used statistical software SPSS version 22.0 for Windows statistical package.
RESULTS
RESULTS
Of 4917 mycobacterial isolates cultured, 6.4% [317/4917, 95% confidence interval (CI) 5.8%-7.2%] were confirmed as NTM, among which 7.7% (287/3709, 95% CI 6.9%-8.6%) were from the southern region. In inland and coastal China, 87.7% (95% CI 78.7%-93.2%) and 50.0% (95% CI 43.7%-56.3%) of isolates, respectively, were slow-growing mycobacteria (SGM), with the remaining rapid growing mycobacteria (RGM). A total of 29 species were detected, Mycobacterium abscessus had higher clarithromycin-inducible resistance rates than M. massiliense (65.67% vs 2.22%). M. kansasii presented lower resistance rates in linezolid and moxifloxacin than M. avium-intracellulare complex (3.23% vs 66.67%, 0 vs 47.22%) and other SGM (3.23% vs 38%, 0 vs 26%).
CONCLUSIONS
CONCLUSIONS
More NTM pulmonary disease was observed in the south and coastal China (P < 0.01). SGM was widely distributed, and more RGM are present in southern and coastal China (P < 0.01). The antimicrobial resistance spectrum of different NTM species was significantly different and accurate species identification would be facilitated to NTM pulmonary disease treatment.
Identifiants
pubmed: 33926548
doi: 10.1186/s40249-021-00844-1
pii: 10.1186/s40249-021-00844-1
pmc: PMC8082609
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Subventions
Organisme : National Major Science and Technology Projects of China
ID : 2017ZX10304402-001-015
Organisme : Chinese Center for Disease Control and Prevention
ID : 59911905
Références
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29437627
Respiration. 2016;91(5):386-402
pubmed: 27207809
J Infect Chemother. 2019 Feb;25(2):117-123
pubmed: 30447882
Emerg Microbes Infect. 2018 Jul 4;7(1):114
pubmed: 29973586
Emerg Infect Dis. 2019 Oct;25(10):1991-1993
pubmed: 31538923
N Engl J Med. 2012 Jun 7;366(23):2161-70
pubmed: 22670902
Emerg Infect Dis. 2014 Oct;20(10):1769-70
pubmed: 25271594
Eur Respir J. 2017 Apr 26;49(4):
pubmed: 28446559
Thorax. 2007 Aug;62(8):661-6
pubmed: 17311842
Thorax. 2017 Nov;72(11):969-970
pubmed: 29054887
Clin Microbiol Infect. 2019 Mar;25(3):379.e1-379.e7
pubmed: 29906595
Diagn Microbiol Infect Dis. 2019 Feb;93(2):107-111
pubmed: 30236529
PLoS One. 2014 Dec 02;9(12):e114353
pubmed: 25463697
Eur Respir J. 2017 Mar 8;49(3):
pubmed: 28275172
Clin Microbiol Infect. 2018 Jun;24(6):599-603
pubmed: 29174730
Pathology. 2015 Dec;47(7):678-82
pubmed: 26517625
Ann Am Thorac Soc. 2014 Jan;11(1):23-9
pubmed: 24298907
Epidemiol Infect. 2019 Sep 11;147:e269
pubmed: 31506134
Biomed Environ Sci. 2017 Jul;30(7):517-525
pubmed: 28756811
Biomed Res Int. 2016;2016:2153910
pubmed: 27882322
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923867
PLoS Negl Trop Dis. 2015 Mar 16;9(3):e0003623
pubmed: 25775117
PLoS One. 2014 Oct 16;9(10):e109736
pubmed: 25330201
Stat Med. 1998 Apr 30;17(8):857-72
pubmed: 9595616
Respirology. 2009 Jan;14(1):12-26
pubmed: 19144045
Emerg Infect Dis. 2012 Mar;18(3):527-8
pubmed: 22376989
Clin Chest Med. 2002 Sep;23(3):585-97
pubmed: 12370994
Diagn Microbiol Infect Dis. 2014 Jul;79(3):355-7
pubmed: 24768296
J Clin Lab Anal. 2014 Sep;28(5):409-14
pubmed: 24652818
Front Microbiol. 2016 Dec 26;7:2097
pubmed: 28082964
Front Public Health. 2020 Jul 28;8:295
pubmed: 32850570
Biomed Res Int. 2015;2015:419392
pubmed: 26351633
Clin Chim Acta. 2016 Sep 1;460:190-5
pubmed: 27380997
J Clin Microbiol. 2019 Sep 24;57(10):
pubmed: 31315954
J Infect. 2016 Dec;73(6):558-567
pubmed: 27717784